A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at ...
Clascoterone 5% topical solution, an anti-androgen that targets the hair follicle androgen receptor without measurable ...
Scientists at EPFL and Johns Hopkins uncover the central role of an enzyme in controlling prostate cancer subtypes and ...
Content creator Jack Joseph has revealed how taking SARMs as a teenager led to liver failure, highlighting the risks of ...
Discover inspiring stories of global progress in primary education, health advancements, conservation efforts and more.
Experts say hair loss treatments such as Rogaine and Propecia are effective and widely available. However, various treatments ...
As per DelveInsight estimates, the total prevalent population of prostate cancer in the 7MM was nearly 8,241,000 cases in 2023. These cases are projected to increase during the forecast period, i.e., ...
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...
University Hospitals Seidman Cancer Center researchers have developed a tool that could identify metastatic prostate cancer ...
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U.S.) has been dosed ...
Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population. A post-hoc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback